Evaluating CLL treatment efficacy
Evaluating CLL treatment efficacy: how to interpret progression-free survival, time to next treatment and MRD?
In recent years we have moved away from chemoimmunotherapy (CIT) toward the use of novel targeted agents, such as BTK and BCL2 inhibitors, which are now the mainstay of therapy both in the frontline and in relapsed settings.
